The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
Fred Saad
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Eric Winquist
No relevant relationships to disclose
Stacey Hubay
No relevant relationships to disclose
Scott R. Berry
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Hazem Assi
No relevant relationships to disclose
Eric Levesque
No relevant relationships to disclose
Nathalie Aucoin
Consultant or Advisory Role - Sanofi
Piotr Czaykowski
Research Funding - Sanofi
Jean-Baptiste Lattouf
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Karine Alloul
Employment or Leadership Position - Sanofi
John Stewart
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Srikala S. Sridhar
No relevant relationships to disclose